The 2026 EASO pharmacotherapy update formalised this evidence by ranking tirzepatide above semaglutide for obesity management, while simultaneously supporting semaglutide as the better-documented agent for liver fibrosis improvement in metabolic dysfunction-associated steatohepatitis (MASH), based on more mature phase 3 ESSENCE trial data [1]
While transitional assistance has stepped in for some, nearly 60% of written GLP-1 prescriptions remained unfilled in the first half of 2023
Front Med (2020) 7:607186
Incubation with GLP-1 and the GLP-1R agonist, exenatide, triggered a cAMP response in MEG-01 cells, with exenatide significantly reducing platelet aggregation induced by thrombin, ADP, and collagen
Simultaneously, it enhances VPS34 activity through the direct phosphorylation of beclin-1 in pro-autophagic complexes
But they are not the same drug, and the differences between them are clinically significant